Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.2900 on 2017-11-20

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2008-11-21

TOP PICK
Abbott Labs (ABT-N)
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
biotechnology/pharmaceutical
Walter Gerasimowicz

Chairman and CEO, Meditron Asset Management

Price: $51.520
Owned: Yes

2013-09-19

TOP PICK
Abbott Labs (ABT-N)

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $35.340
Owned: Yes

2013-11-01

TOP PICK
Abbott Labs (ABT-N)

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $36.960
Owned: Yes

2014-02-18

BUY
Abbott Labs (ABT-N)

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $38.930
Owned: Yes

2011-10-19

HOLD
Abbott Labs (ABT-N)
The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $53.250
Owned: No

2012-04-19

BUY
Abbott Labs (ABT-N)
This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $59.510
Owned: No

2014-04-09

DON'T BUY
Abbott Labs (ABT-N)

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $37.630
Owned: No

2015-09-17

COMMENT
Abbott Labs (ABT-N)

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $44.240
Owned: No

2015-04-27

BUY on WEAKNESS
Abbott Labs (ABT-N)

He would wait for some sort of correction. Likes this. It is a leader in its field.

biotechnology/pharmaceutical
Peter Brieger

Chairman & Chief Executive Officer, GlobeInvestment Capital Management

Price: $47.490
Owned: Yes

2016-06-22

COMMENT
Abbott Labs (ABT-N)

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $38.740
Owned: Yes

2017-02-22

COMMENT
Abbott Labs (ABT-N)

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $45.010
Owned: Unknown

2017-05-10

COMMENT
Abbott Labs (ABT-N)

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $44.500
Owned: No

2013-03-07

BUY
Abbott Labs (ABT-N)

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

biotechnology/pharmaceutical
Patrick Horan

Portfolio Manager, Agilith Capital Inc

Price: $34.430
Owned: Yes

2007-08-29

BUY
Abbott Labs (ABT-N)
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
biotechnology/pharmaceutical
Norman Levine

Managing Director, Portfolio Management Corp

Price: $51.490
Owned: Unknown

2011-10-24

COMMENT
Abbott Labs (ABT-N)
Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
biotechnology/pharmaceutical
Norman Levine

Managing Director, Portfolio Management Corp

Price: $53.450
Owned: No

Showing 1 to 15 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.